NLRC5 Human Pre-designed siRNA Set A contains three designed siRNAs for NLRC5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NLRP1 Human Pre-designed siRNA Set A contains three designed siRNAs for NLRP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NLRP10 Human Pre-designed siRNA Set A contains three designed siRNAs for NLRP10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NLRP11 Human Pre-designed siRNA Set A contains three designed siRNAs for NLRP11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NLRP12 Human Pre-designed siRNA Set A contains three designed siRNAs for NLRP12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NLRP14 Human Pre-designed siRNA Set A contains three designed siRNAs for NLRP14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nlrp1a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nlrp1a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nlrp1a Rat Pre-designed siRNA Set A contains three designed siRNAs for Nlrp1a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

NLRP2 Human Pre-designed siRNA Set A contains three designed siRNAs for NLRP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NLRP3 Human Pre-designed siRNA Set A contains three designed siRNAs for NLRP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nlrp3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nlrp3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nlrp3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nlrp3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

NLRP3-IN-2 (Standard) is the analytical standard of NLRP3-IN-2. This product is intended for research and analytical applications. NLRP3-IN-2, an intermediate substrate in the synthesis of glyburide, inhibits the formation of the NLRP3 inflammasome in cardiomyocytes and limits the infarct size following myocardial ischemia/reperfusion in the mouse, without affecting glucose metabolism[1].

NLRP3-IN-30 (Compound A14) is a potent NLRP3 inhibitor, with an IC50 of 44.43 nM. NLRP3-IN-30 has highly oral bioavailability (F is 83.09% in mice)[1].

NLRP3-IN-31 (Comp 14) is a NLRP3 inhibitor, with an IC50 of 0.3-0.5 μM[1].

NLRP3-IN-32 (compound 7a), a 3, 4-dihydronaphthalene-1(2H)-one derivative, is a potential NLRP3 inflammatory vesicles inhibitor. NLRP3-IN-32 can block the assembly and activation of NLRP3 inflammasome by down-regulating the expression of NLPR3 and apoptosis-associated speck-like protein containing a CARD (ASC), and inhibiting the production of reactive oxygen species (ROS) and other inflammatory mediators. NLRP3-IN-32 inhibits the phosphorylation […]

NLRP3-IN-33 (Compound 12o) is a blood-brain barrier permeable inhibitor of AChE and BChE, with IC50 values of 1.02 μM and 7.03 μM against hAChE and hBChE respectively. NLRP3-IN-33 possesses antioxidant, anti-inflammatory, and metal chelating activities, making it a potential candidate for research in Alzheimer’s disease (AD)[1].

NLRP3-IN-34 (Compound T10) is an inhibitor for NLRP3 inflammasome. NLRP3-IN-34 inhibits ROS production, NLRP3 inflammasome-dependent IL-1β production (IC50 is 0.48 μM in cells J774A.1), and inhibits pyroptosis. NLRP3-IN-34 exhibits anti-inflammatory activity against DSS-induced peritonitis[1].

NLRP3-IN-35 (compound 11) is an NLRP3 inhibitor (IC50 < 1 μM)[1].

NLRP3-IN-37 (Compound 23) is a NLRP3 inhibitor (EC50: 5 nM). NLRP3-IN-37 can be used for NLRP3 related research, such as gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer’s Disease, Parkinson’s Disease and traumatic brain injury[1].

NLRP3-IN-38 (Compound 18) is an inhibitor for NOD-like receptor protein 3 (NLRP3), that inhibits NLRP3 inflammasome activation with an EC50 of 23 nM[1].

NLRP4 Human Pre-designed siRNA Set A contains three designed siRNAs for NLRP4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NLRP5 Human Pre-designed siRNA Set A contains three designed siRNAs for NLRP5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NLRP6 Human Pre-designed siRNA Set A contains three designed siRNAs for NLRP6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NLRP7 Human Pre-designed siRNA Set A contains three designed siRNAs for NLRP7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NLRP9 Human Pre-designed siRNA Set A contains three designed siRNAs for NLRP9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NLRX1 Human Pre-designed siRNA Set A contains three designed siRNAs for NLRX1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nlrx1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nlrx1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nlrx1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Nlrx1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

NMB Human Pre-designed siRNA Set A contains three designed siRNAs for NMB gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NMBR Human Pre-designed siRNA Set A contains three designed siRNAs for NMBR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NMD3 Human Pre-designed siRNA Set A contains three designed siRNAs for NMD3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NMD670 is an orally active partial inhibitor of the skeletal muscle-specific chloride channel ClC-1. NMD670 increases muscle excitability in response to movement commands, enhances neuromuscular transmission, restores muscle function and improves muscle mobility. NMD670 has a favorable safety profile and improves muscle function in rats in a MG rat model[1].

NME1 Human Pre-designed siRNA Set A contains three designed siRNAs for NME1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NME1-NME2 Human Pre-designed siRNA Set A contains three designed siRNAs for NME1-NME2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NME2 Human Pre-designed siRNA Set A contains three designed siRNAs for NME2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NME3 Human Pre-designed siRNA Set A contains three designed siRNAs for NME3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NME4 Human Pre-designed siRNA Set A contains three designed siRNAs for NME4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NME5 Human Pre-designed siRNA Set A contains three designed siRNAs for NME5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NME6 Human Pre-designed siRNA Set A contains three designed siRNAs for NME6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NME7 Human Pre-designed siRNA Set A contains three designed siRNAs for NME7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NME8 Human Pre-designed siRNA Set A contains three designed siRNAs for NME8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NME9 Human Pre-designed siRNA Set A contains three designed siRNAs for NME9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NMI Human Pre-designed siRNA Set A contains three designed siRNAs for NMI gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NMNAT1 Human Pre-designed siRNA Set A contains three designed siRNAs for NMNAT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NMNAT2 Human Pre-designed siRNA Set A contains three designed siRNAs for NMNAT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.